Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OncLive Global Expo
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2015 European Cancer Congress
Oncology Conference Multimedia
View more videos >>
Dr. Raffit Hassan on Avelumab in Unresectable Mesothelioma
Dr. Poortmans on Impact of Multidisciplinary Approach on Side Effect Management
Dr. Lambertini on Preserving Ovarian Function and Fertility During Chemotherapy Treatment
Oncology Conference Articles
2015 European Cancer Congress Highlights
Laura Jones reports findings from the 2015 European Cancer Congress, including impressive results for nivolumab and cabozantinib in renal cell carcinoma, practice-changing data for everolimus and a new radionuclide in neuroendocrine tumors, pivotal findings in lung cancer and bladder cancer for atezolizumab, and more.
Telotristat Etiprate Curbs Carcinoid Syndrome in Neuroendocrine Tumors
Treatment with telotristat etiprate reduced the average number of daily bowel movements by up to 35% for patients with carcinoid syndrome that was not adequately controlled by a somatostatin analog.
Erlotinib/Bevacizumab Effective in EGFR T790M-Mutant NSCLC
Treatment with the frontline combination of erlotinib and bevacizumab was highly effective in patients with advanced nonâ€“small cell lung cancer who harbored an EGFR T790M mutation.
Longer Follow-up Confirms Nivolumab OS Benefit in Nonsquamous NSCLC
Treatment with nivolumab reduced the risk of death by 28% compared with docetaxel for patients with previously treated nonsquamous nonâ€“small cell lung cancer.
Novel Antibody-Drug Conjugate Shows Promise in SCLC
The antibody-drug conjugate rovalpituzumab tesirine demonstrated activity across a range of patients with relapsed and refractory small-cell lung cancer.
Updated Pembrolizumab Lung Cancer Data Presented as FDA Decision Nears
Data from the pivotal KEYNOTE-001 trial showing pembrolizumab's efficacy in pretreated nonâ€“small cell lung cancer (NSCLC) were presented at the 2015 European Cancer Congress, just days before the FDA is scheduled to make its approval decision on the PD-1 inhibitor in this setting.
Fosaprepitant Improves Emesis Control in Women Receiving Chemoradiotherapy for Cervical Cancer
Adding fosaprepitant (Emend) to an antiemetic regimen significantly improved emesis control versus standard care in women receiving radiotherapy and cisplatin for cervical cancer.
Dabrafenib/Trametinib Combo Improves OS Versus Vemurafenib in Advanced Melanoma
The combination of dabrafenib plus trametinib improved overall survival by 7.6 months compared with single-agent vemurafenib in patients with unresectable or metastatic BRAFV600E/K-mutant melanoma.
T-VEC/Pembrolizumab Combination Demonstrates Safety in Melanoma
The combination of the attenuated oncolytic virus talimogene laherparepvec and the immune checkpoint inhibitor pembrolizumab for unresectable melanoma has passed an early safety evaluation.
Atezolizumab Provides Viable Treatment Option in Metastatic Urothelial Carcinoma
Second-line atezolizumab demonstrated significant clinical benefit in patients with metastatic urothelial carcinoma who had a poor prognosis after progressing following platinum-based chemotherapy.
Two Pivotal Studies Show Efficacy of Atezolizumab in PD-L1-Positive NSCLC
Inhibition of PD-L1 with atezolizumab demonstrated significant clinical efficacy as monotherapy in patients with advanced non-small cell lung cancer.
Nivolumab Before Ipilimumab Has Greater Efficacy, Similar AEs
Two strategies of sequential immunotherapy for advanced melanoma showed similar safety and tolerability but substantially different efficacy.
Most Brain Metastases Have Actionable Mutations Not Found in Primary Tumor
More than half of brain metastases harbored clinically actionable genetic alterations that were distinct from those associated with the primary tumor.
Targeted Radionuclide Improves PFS Over Octreotide LAR in Midgut NETs
Treatment with the novel peptide receptor radionuclide therapy Lutathera significantly increased progression-free survival over octreotide LAR in patients with advanced midgut neuroendocrine tumors.
Everolimus May Be New Standard of Care in Advanced Lung, GI NETs
Treatment with everolimus was associated with a 52% improvement in median progression-free survival compared with placebo in patients with advanced lung and gastrointestinal neuroendocrine tumors.
Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma
More than a fifth of patients with previously treated metastatic nasopharyngeal carcinoma showed a measurable response when treated with the immune checkpoint inhibitor pembrolizumab.
Trabectedin OS Data Unclear in Phase III Sarcoma Study
The final analysis of phase III data for trabectedin were consistent with interim results by showing a lack of improvement for the primary endpoint of overall survival in patients with advanced soft tissue sarcoma.
Nivolumab Extends Survival in Advanced Renal Cell Carcinoma
Nivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.
Second-Line Cabozantinib Improves PFS in Advanced RCC
Second-line treatment with cabozantinib reduced the risk of progression or death by 42% compared with everolimus in patients with advanced renal cell carcinoma.
FDA Approvals in Myeloma and ITP, Applications Accepted in Myeloma and More
Neoadjuvant Therapy in the Treatment of Melanoma
Dr. Raje Highlights Treatment Options for Relapsed Multiple Myeloma
Quest Continues to Extend Reach of Immunotherapy, PARP Inhibitors in Ovarian Cancer
MONALEESA-2 and Choosing Among the CDK4/6
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.